We welcomed two special guests, Dr. Stacy Lindborg, CEO of IMUNON, and Dr. Premal Thaker, Gynecologic Oncologist at Washington University, to discuss the results of the OVATION 2 Study and the latest ...
Verseon International Corporation has announced that its noval AI technology, VersAI™, demonstrates superior prediction accuracy compared to current state-of-the ...
Presented at ESMO 2024, the Phase 2 PHAROS trial revealed that BRAFTOVI® and MEKTOVI® combination therapy has significant long-term benefits for patients with BRAF V600E-mutant metastatic non-small ...